Monday U.S. and Canada Christmas Day, Markets Closed Tuesday U.S. Economic ...
EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of its underwritten confidentially marketed public...
CEL-SCI Corporation (NYSE American: CVM) today announced it has held a productive pre-submission meeting with Canada’s regulator to determine the best regulatory path toward market approval. Based...
CEL-SCI Corporation (NYSE American: CVM) today reported new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma of the head...
CEL-SCI Corporation (NYSE American: CVM) today announced it will present new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma...
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2022, as well as key clinical and corporate developments.
CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2022, as well as key clinical and corporate developments.
Tuesday U.S. Economic Lookahead Trade in goods, advance report (Nov) S&P ...
CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.